FDA approves Moderna’s mRNA flu vaccine after initial pushback
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced Wednesday. mFLUSIVA, approved for adults ages 50 and older, is the first influenza vaccine using mRNA technology to receive FDA approval. “This approval also reflects the ongoing potential of our mRNA platform to…